<DOC>
	<DOCNO>NCT02307695</DOCNO>
	<brief_summary>To investigate whether saxagliptin could reduce fluctuation glycemia improve glycemic control type 1 diabetes mechanisms suppress glucagon secretion , improve beta cell function , re-regulating T cell immune system .</brief_summary>
	<brief_title>The Effect Saxagliptin Glucose Fluctuation Immune Regulation Patients With Type 1 Diabetes</brief_title>
	<detailed_description>Type 1 diabetes mellitus ( T1DM ) characterize immune mediate beta-cell destruction . Due imbalance glucagon insulin , long-term T1DM patient experience frequent hypoglycaemia high glucose variability despite multiple daily injection insulin . Dipeptidyl peptidase 4 ( DPP-4 ) inhibitors new class anti-diabetic agent widely use clinical practice improve glycemic control protect β-cell function patient type 2 diabetes mellitus ( T2DM ) . Saxagliptin , DPP-4 inhibitor , improve glycemic control patient T2DM increase endogenous active , intact glucagon-like peptide 1 glucose-dependent insulinotropic polypeptide response food , augments insulin secretion decrease glucagon release . This mechanism lead reduction glucose variation . In pilot study , incretin-based therapy patient T1DM improve glucose control reduce hypoglycemia , mechanism probably regulate glucagon level . In type 1 diabetic mouse model , DPP-4 inhibitor preserve beta-cell mass stimulate beta-cell replication . Interestingly , DPP-4 also know cluster differentiation antigen 26 ( CD26 ) .It express membrane many type lymphocyte , e.g . T , B natural killer ( NK ) cell , involve cellular function . CD26 play key role many aspect lymphocyte function beyond DPP-4 enzymatic activity.These observation make promising therapeutic target . Recently , attention saxagliptin mainly focus type 2 diabetes , data type 1 diabetes rare . We go carry phase 4 study testify hypothesis saxagliptin could reduce fluctuation glycemia improve glycemic control type 1 diabetes mechanisms suppress glucagon secretion , improve beta cell function , re-regulating T cell immune system .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedure ; 2 . Diagnosed type 1 diabetes ; 3 . Men woman 12 65 year age time consent upon Visit 1. ; 4 . Positivity least one four islet autoantibody ( IA2A、IAA、GADA、ZnT8A ) ; 5 . 6.5 % ≤ HbA1c ≤10.0 % . 1. type 2 diabetes； 2 . Evidence chronic acute complication diabetes unstable require hospitalization； 3 . Evidence disease stress； 4 . History administration antihyperglycemic therapy ( insulin ) 12 week prior Visit 1； 5 . Have history , currently , acute chronic pancreatitis； 6 . Immunocompromised individual patient undergone organ transplantation patient diagnose HIV patient agranulocytosis； 7 . Evidence chronic acute infection； 8 . Active liver disease and/or significant abnormal liver function define Aspartate transaminase ( AST ) ≥3x Upper Limit Normal ( ULN ) and/or Alanine aminotransferase ( ALT ) ≥3x Upper Limit Normal ( ULN ) ； 9 . History unstable rapidly progress renal disease , creatinine clearance ( CrCl ) ≤50ml/min ; 10 . Congestive heart failure define New York Heart Association ( NYHA ) class III IV and/or leave ventricular ejection fraction ≤ 40 % ； 11 . Rheumatoid arthritis autoimmune disease ( except AITD ) ; 12 . Hypersensitivity saxagliptin； 13 . History drug allergy allergic disease 14 . History alcohol abuse , illegal drug abuse , mental disease disease eligible study 15 . Pregnant breastfeed patients； 16 . Patients diseases judgement investigator would compromise patient 's safety successful participation clinical study 17 . Any condition , opinion investigator , participation study may pose significant risk patient could render patient unable successfully complete study 18 . Any disease condition investigator feel would interfere trial ; 19 . Treatment immunosuppressive agent systemic glucocorticoid replacement therapy . Inhaled , local inject topical use glucocorticoid allow last 90 day prior Visit 1 ; 20 . Participation clinical study last 90 day prior Visit 1 ; 21 . Patients participate clinical study ; 22 . Treatment strong cytochrome P450 3A4/5 ( CYP3A4/5 ) inhibitor contraindication therapy outline saxagliptin package insert ; 23 . History haemoglobinopathy ( sickle cell anaemia thalassemia , sideroblastic anaemia ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Saxagliptin</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Glycemic variability</keyword>
	<keyword>C-Peptide</keyword>
</DOC>